Crispr stock forecast 2025.

N/A. Editas Medicine is leading the way in using CRISPR to treat rare genetic eye diseases. The company reported preliminary results in September 2021 from a phase 1/2 study evaluating EDIT-101 in ...Asking AI for help finding triple-digit return biotech stocks reminds investors not to avoid the big names. CRISPR Therapeutics (): The one name that AI produced that isn’t a large-cap stock may ...Stock Price Forecast. The 1 analysts offering 12-month price forecasts for UpHealth Inc have a median target of 3.50, with a high estimate of 3.50 and a low estimate of 3.50.The average CRISPR Therapeutics AG stock forecast 2024 represents a -25.46% decrease from the last price of $68.6500015258789. For CRISPR Therapeutics AG stock forecast for 2025, 12 predictions are offered for each month of 2025 with average CRISPR Therapeutics AG stock forecast of $49.41, a high forecast of $51.16, and a low forecast of $46.49.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

21 analysts have issued 1-year price objectives for Intellia Therapeutics' stock. Their NTLA share price targets range from $40.00 to $136.00. On average, they expect the company's stock price to reach $77.70 in the next year. This suggests a possible upside of 150.4% from the stock's current price.The 68 analysts offering price forecasts for CRISPR Therapeutics have a median target of 81.82, with a high estimate of 168.00 and a low estimate of 37.00. The median estimate represents a 83.90 ...

Nov 14, 2023 · The CRISPR Therapeutics stock prediction results are shown below and presented as a graph, table and text information. CRISPR Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for CRISPR Therapeutics analysts is $ 87.78. Today 200 Day Moving Average is the ... 32.69%. Dividend Yield. N/A. More importantly, CRISPR Therapeutics' financial results should improve in the next five years. The company is on the verge of receiving approval for exa-cel, a gene ...Target values for the price of one Editas Medicine share for Aug 2025. The weighted average target price per Editas Medicine share in Aug 2025 is: 18.97. In Aug, the Negative dynamics for Momo shares will prevail with possible monthly volatility of 19.739% volatility is expected. Pessimistic target level: 17.66. Optimistic target level: 22.00.Nov 14, 2023 · The CRISPR Therapeutics stock prediction results are shown below and presented as a graph, table and text information. CRISPR Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for CRISPR Therapeutics analysts is $ 87.78. Today 200 Day Moving Average is the ...

All stock predictions. ... stock consensus forecasts for 2025. Last update: 06/17/2023, 02:26 AM ... Brief information about CRISPR Therapeutics AG. Ticker: CRSP

The first chart below shows the global market size of CRISPR gene editing in 2019 and a forecast for 2030. The market is set to increase by a mind-boggling 1,179% to reach more than $10 billion by ...

Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business.CRISPR Technologies: 191,416% implied sales growth by 2025. Did I mention that clinical-stage biotech stocks are a great source of jaw-dropping growth over the next decade?The current CRISPR Therapeutics AG [ CRSP] share price is $66.73. The Score for CRSP is 52, which is 4% above its historic median score of 50, and infers lower risk than …WebCRISPR Therapeutics AG research and ratings by Barron's. View CRSP revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Nokia will start 2025 at $4.39, then soar to $4.44 within the first six months of the year and finish 2025 at $4.50. That means +15% from today. Nokia Stock Forecast 2030-2034. In this period, the Nokia price would rise from $7.31 to $9.18, which is +26%.Future Return on Equity Future ROE: CRSP's Return on Equity is forecast to be low in 3 years time (2%). Discover growth companies High growth companies in the Pharmaceuticals-biotech industry View Past PerformanceFind the latest Verve Therapeutics, Inc. (VERV) stock quote, history, news and other vital information to help you with your stock trading and investing.

You value AMD way out in 2025 with a multiple of 25, which is around the current market multiple. The market grows on average around 5-6% per year. Even in 2025, AMD will be growing far faster ...Mar 9, 2021 · CRISPR Therapeutics AG Stock Prediction 2025. The CRISPR Therapeutics AG stock prediction for 2025 is currently $ 114.05, assuming that CRISPR Therapeutics AG shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 70.91% increase in the CRSP stock price. Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $78.65 with a high forecast of $136.00 and a low forecast of $31.00. The average price target represents a 151.68% change from the last price of $31.25. Highest Price Target $136.00.Dec 1, 2023 · Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its quarterly earnings data on Tuesday, November, 7th. The company reported ($2.70) EPS for the quarter, beating the consensus estimate of ($5.25) by $2.55. The company earned $0.47 million during the quarter. Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business. The stock trades at only ~2x 2025 EV/S targets, but investors face a bumpy road ahead. ... The company forecast a revenue target of $75 million for 2023 jumping to $286 million in 2024 and ...Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business.

CRISPR Therapeutics (CRSP-0.74%) has been a volatile stock over the past couple of years. Lately, the gene-editing company's shares have been trading for under $51 a share, but I believe they ...That's an eye catching number but take a step back and think about it. We hit $5.00 last week. If it doubles in 2021 that's $10.00 and if it doubles again in 2 years by 2023 that's $20.00 leaving 2024 for 30% growth to 26.00. In a growing EV market, with a fully differentiated product.

CRSP stock has rallied from $34 to $107 off the recent bottom compared to the S&P which moved 60% over the same period, with the resumption of economic activities as lockdowns are gradually lifted ...Dec 4, 2023 · Nokia will start 2030 at $6.41, then soar to $6.54 within the first half of the year, and finish 2030 at $6.68. It is about +88% from today. Nokia Stock Price Forecast 2023-2024. Nokia price started in 2023 at $4.64. Today, Nokia traded at $3.49, so the price decreased by -25% from the beginning of the year. Did I mention that clinical-stage biotech stocks are a great source of jaw-dropping growth over the next decade? CRISPR Therapeutics (CRSP-6.39%), a company leaning on gene-editing technology to precisely alter genomic DNA and tackle hard-to-treat diseases, is expected to see sales climb from $719,000 … See moreFind real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business.Stock Price Forecast. The 10 analysts offering 12-month price forecasts for JetBlue Airways Corp have a median target of 4.25, with a high estimate of 6.00 and a low estimate of 3.00. The median ...Stock Price Forecast. The 3 analysts offering 12-month price forecasts for UpHealth Inc have a median target of 7.00, with a high estimate of 9.75 and a low estimate of 4.30. The median estimate ...According to 30 stock analysts, the average 12-month stock price forecast for Tesla stock is $238.87, which predicts a decrease of -2.16%. The lowest target is $85 and the highest is $380. On average, analysts rate Tesla stock as a hold.My valuation implies that Alibaba's shares will be worth $138 in 2025, and this implies a three-year investment CAGR of +9.4% based on the company's last traded share price of $105.42 as of March ...CRSP stock has rallied from $34 to $107 off the recent bottom compared to the S&P which moved 60% over the same period, with the resumption of economic activities as lockdowns are gradually lifted ...Though Nokia had some major mistakes in the past few years, its business is back on track with the expansion of the 5G sector. Moreover, it is expected to be profitable as well, with expected 2021 ...

Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Ginkgo Bioworks Holdings Inc have a median target of 3.00, with a high estimate of 7.00 and a low estimate of 1.25. The ...

It is projected to grow at a compounded annual growth rate of 8% to be valued at $14 billion by 2030. Under the terms of the deal, Vertex paid CRISPR $100 million up front for those rights and ...

Stock Price Forecast. The 28 analysts offering 12-month price forecasts for Spotify Technology SA have a median target of 195.16, with a high estimate of 256.79 and a low estimate of 151.00.Find real-time NOK - Nokia Oyj stock quotes, company profile, news and forecasts from CNN Business. ... EPS forecast (this quarter) $0.17: Annual revenue (last year) $26.2B: Annual profit (last year)Aug 14, 2023 · It is projected to grow at a compounded annual growth rate of 8% to be valued at $14 billion by 2030. Under the terms of the deal, Vertex paid CRISPR $100 million up front for those rights and ... Stock Price Forecast. The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00. The ...The weighted average target price per CRISPR Therapeutics share in Nov 2025 is: 76.83. In Nov, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 18.142% volatility is expected. Pessimistic target level: 69.33. Optimistic target level: 84.70.Nov 19, 2023 · CRISPR Therapeutics has a 52 week low of $37.55 and a 52 week high of $72.00. The stock has a market cap of $5.39 billion, a price-to-earnings ratio of -15.19 and a beta of 1.57. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings results on Monday, November 6th. The company reported ($1.41) EPS for the ... 3 hari yang lalu ... Get the latest Crispr Therapeutics AG (CRSP) real-time quote, historical performance, charts, and other financial information to help you ...VRTX Stock 12 Months Forecast. Based on 20 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $392.58 with a high forecast of $456.00 and a low forecast of $325.00. The average price target represents a 5.07% change from the last price of $373.65.Despite a 26% rise over the last month or so, CRSP stock is still down 20% year-t0-date. A few months back we discussed that investors may get better levels to enter CRSP stock after it surged 3x ...Intellia Therapeutics will start 2025 at $39.50, then soar to $40.96 within the first six months of the year and finish 2025 at $47.84. That means +51% from today. Intellia Therapeutics Stock Forecast 2030-2034. In this period, the Intellia Therapeutics price would rise from $91.85 to $115.11, which is +25%.If the consensus price target set by Wall Street analysts is to be believed, CRISPR Therapeutics (CRSP-3.43%) stock is going to rise by 49% within the next 12 months.Forecast for March 2025. It is predicted that the price of one CRISPR Therapeutics share in will be in the range of $35.26 to $41.70. The width of this range …Web

So, when comparing one stock to another in a different industry, it's best make relative comparisons to that stock's respective industry values. -240.84% -224.88%The CRISPR Therapeutics stock price fell by -0.738% on the last day (Friday, 24th Nov 2023) from $70.49 to $69.97. During the last trading day the stock fluctuated 5.38% from a day low at $69.65 to a day high of $73.40. The price has risen in 7 of the last 10 days and is up by 36.5% over the past 2 weeks. Volume fell on the last day along with ...Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Adaptive Biotechnologies Corp have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 6.00 ...CRISPR Therapeutics appears to be about ... This means that as a common stock investor in CRISPR ... The assumption of 0% penetration in 2025 and 10% in 2026 is likely far too ...Instagram:https://instagram. msft dividend daterich people who donate moneynio stock price prediction 2025best equity income funds Stock Quote & Chart. (Common Stock) 1:08 PM EST on Nov 17, 2023. Change. Volume. fihbxaetna dental savings plans My valuation implies that Alibaba's shares will be worth $138 in 2025, and this implies a three-year investment CAGR of +9.4% based on the company's last traded share price of $105.42 as of March ...Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Adaptive Biotechnologies Corp have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 6.00 ... best landlord insurance in florida Most bullish — Tesla stock rises to $251, up 104%. Wall Street analysts expect the stock to end 2023 at $251. Less bullish ($119, down 3.3%). This is based on applying Apple’s P/E ratio of 21 ...Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Mind Medicine (MindMed) Inc have a median target of 22.00, with a high estimate of 75.00 and a low estimate of 7.00. The ...Exro Technologies Stock Forecast, EXROF stock price prediction. Price target in 14 days: 1.129 USD. ... Exro Technologies Inc Stock Price Forecast for 2025: January ...